耐酒石酸酸性磷酸酶(ACP5)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5)
TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase
- 編號(hào)USEA902Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.312-20ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.129ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1323 ¥ 1890 ¥ 8505 ¥ 16065 ¥ 132300
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)耐酒石酸酸性磷酸酶(ACP5)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的耐酒石酸酸性磷酸酶(ACP5)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 97-104 | 101 |
| EDTA plasma(n=5) | 89-96 | 92 |
| heparin plasma(n=5) | 78-95 | 83 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的耐酒石酸酸性磷酸酶(ACP5)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中耐酒石酸酸性磷酸酶(ACP5)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-98% | 80-92% | 78-104% | 89-103% |
| EDTA plasma(n=5) | 99-105% | 90-99% | 88-102% | 89-101% |
| heparin plasma(n=5) | 85-101% | 81-101% | 84-101% | 97-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將耐酒石酸酸性磷酸酶(ACP5)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的耐酒石酸酸性磷酸酶(ACP5)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的耐酒石酸酸性磷酸酶(ACP5)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的耐酒石酸酸性磷酸酶(ACP5)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA902Hu01 | 耐酒石酸酸性磷酸酶(ACP5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA902Hu01 | 耐酒石酸酸性磷酸酶(ACP5)多克隆抗體 | WB; IHC |
| UMAA902Hu22 | 耐酒石酸酸性磷酸酶(ACP5)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA902Hu | 耐酒石酸酸性磷酸酶(ACP5)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA902Hu | 耐酒石酸酸性磷酸酶(ACP5)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Archives of Oral Biology | Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats [ScienceDirect: S0003996912001021] |
| Life Sciences | Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes [PubMed: 23357248] |
| International Journal of Cardiology | Valvular osteoclasts in calcification and aortic valve stenosis severity. [Pubmed: 23452891] |
| Evidence-Based Complementary and Alternative Medicine | Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice [Pubmed:25737735] |
| Advances in Medical Sciences | The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats [PubMed: 26569440] |
| Bone | The effects of strength training and raloxifene on bone health in aging ovariectomized rats [Pubmed:26812611] |
| Journal of Clinical Medicine Research | In?Vitro?and In?Vivo?Effects?of?Gracilaria?verrucosa?Extracts?on?Osteoclast?Differentiation. [pubmed:28335442] |
| Biomedicine & Pharmacotherapy | Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats [S0753332216322752] |
| Clinical Trials in Degenerative Diseases | Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial [issn:2542-3975] |
| Scientific Reports | Evidence for excessive osteoclast activation in SIRT6 null mice [Pubmed:30030453] |
| International?Journal?of?Molecular?Sciences? | Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo [Pubmed:29562730] |
| Experimental Gerontology | The decline of whole-body glucose metabolism in ovariectomized rats [Pubmed: 30292771] |
| Bone?Research | NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts [Pubmed: 30455992] |
| Cell Death & Disease | QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism [Pubmed: 32382069] |
| Effect of Corticopuncture (CP), Photobiomodulation (PBM) and the Combined Method on the Rate of Tooth Movement and Root Resorption: A Molecular, Histological … [] | |
| Evid Based Complement Alternat Med | Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway [34512780] |
